Breast Cancer

SWOG S1202: A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor (AI)-Associated Musculoskeletal Symptoms in Women with Early Stage Breast Cancer

This study is for women, who have been identified as having a history of hormone receptor positive breast cancer, are post-menopausal, are being treated with an aromatase inhibitor, and are experiencing joint pain.


The purpose of this study is to assess the effects of the medication duloxetine compared to placebo on joint pain that is associated with taking aromatase inhibitors. Researchers on this study want to see if the pain relieving effects of the drug work for this type of pain.

Patients will take duloxetine or placebo for a total of 13 weeks.  Once finished taking the study drug, patients will visit the doctor’s office at 24 weeks for a final follow-up visit.

Have Questions?

We can help, contact one of our program coordinators today.

Center for Women's Health; Kathleen Ludwig (989) 837-9070

MidMichigan Medical Center - Gratiot; Candy Bendon (989) 466-7253

Or email at

Related Locations